查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1943710

類癌症候群腹瀉治療市場 - 全球產業規模、佔有率、趨勢、機會及預測（按治療類型、最終用戶、地區和競爭格局分類，2021-2031年）

Carcinoid Syndrome Diarrhea Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type ( Chemotherapy, Somatostatin Analog, Therapy, Others), By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球類癌症候群腹瀉治療市場預計將從 2025 年的 42.1 億美元成長到 2031 年的 60.8 億美元，複合年成長率為 6.32%。

該市場涵蓋多種藥物干預措施，例如色氨酸氧化酵素抑制劑和生長抑制素類似物，旨在控制轉移性神經內分泌腫瘤引起的嚴重胃腸道症狀。市場成長的主要驅動力是神經內分泌腫瘤發生率的不斷上升以及分子成像技術的進步，這些進步使得在疾病發生顯著進展之前能夠更早、更準確地進行疾病檢測。例如，歐洲神經內分泌腫瘤學會報告稱，到2024年，約30%的分化良好的小腸神經內分泌腫瘤患者將出現類癌症候群的症狀，這凸顯了擴大患者群體和開發有效對症治療的緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 42.1億美元
市場規模：2031年 60.8億美元
複合年成長率：2026-2031年 6.32%
成長最快的細分市場 生長抑制素類似物（SSA）療法
最大的市場 北美洲

儘管存在這些積極因素，但由於該疾病經常被誤診，市場仍面臨巨大的障礙。其症狀通常與常見的胃腸道疾病（例如大腸激躁症）相似，導致準確診斷和後續治療嚴重延遲。這種診斷延誤使得患者無法及時獲得有效治療方法，並限制了在該專科領域運作的製造商的收入潛力。

市場促進因素

隨著神經內分泌腫瘤發生率的不斷上升，需要長期治療類癌症候群腹瀉的患者數量顯著增加。分子影像等診斷工具的日益普及，使臨床醫生能夠在疾病嚴重前識別出更多分化良好的腫瘤患者，從而持續推動了對控制難治性胃腸道症狀治療方法的需求。根據神經內分泌腫瘤研究基金會2025年9月發布的報告《神經內分泌癌的興起》，美國神經內分泌腫瘤的年齡調整發生率已上升至每10萬人8.52例。日益加重的疾病負擔推動了對現有對症治療藥物的強勁商業性需求。例如，益普生公司在2025年報告稱，其生長抑制素類似物Somatrin的2024年全年銷售額成長了5.6%，這主要得益於需要長期症狀管理的患者群體不斷擴大。

此外，市場成長的驅動力之一是標靶治療。製藥公司正積極推動新型口服藥物的臨床試驗，例如新一代生長抑制素受體促效劑，旨在提高標準療法療效不足時的療效和患者依從性。 2025年11月，Crinetics Pharmaceuticals在其「CAREFNDR III期試驗最新進展」中宣布，首例患者已隨機分配至帕妥昔汀（paltusotine）臨床實驗。帕妥昔汀是一種正在研口服藥物，旨在減少潮熱和排便次數。這一進展標誌著該領域取得了重要里程碑式的進展。這些努力凸顯了製藥業的策略轉型，即為大量遭受類癌症候群控制不佳的患者提供更有效、更方便的解決方案。

市場挑戰

全球類癌綜合症腹瀉治療市場的擴張受到診斷延誤的顯著阻礙，而診斷延誤的主要原因是潛在神經內分泌腫瘤的誤診率很高。由於腹痛和慢性腹瀉等症狀與大腸激躁症（IBS）等功能性疾病非常相似，患者往往需要忍受數年無效的症狀管理，直到惡性腫瘤被正確確診。這種延誤限制了市場潛力，因為它延緩了必要藥物治療的啟動，並有效地縮短了製造商從生長抑制素類似物和色氨酸羥化酶抑製劑等特效藥中獲得收益的時間。

由於這種腫瘤相對罕見，導致全科醫生對其臨床警覺性較低，進一步加劇了及時診斷的難度。根據美國癌症協會2025年的數據，胃腸道神經內分泌腫瘤的年發生率約為每10萬人1-2例。由於發病率低，基層醫療機構很少遇到這種疾病，因此患者的症狀更容易被誤診為更常見的疾病。結果，很大一部分目標患者群體長期未被治療或診斷，人為地抑制了對症治療的需求。

市場趨勢

胜肽受體放射性核種療法（PRRT）的出現徹底改變了難治性類癌症候群腹瀉的治療格局，使其不再僅僅關注腫瘤縮小，而是成為症狀管理的重要選擇。臨床醫生擴大採用標靶放射性配體療法，例如鎦-177多肽，來抑制對傳統生長抑制素類似物不再有效的患者體內血清素和生物活性胺的過度分泌。這種利用核醫進行症狀治療的趨勢也體現在關鍵藥物的強勁商業性表現。例如，諾華公司在2025年1月發布的2024年度報告中揭露，其淨銷售額成長了12%。這一成長主要得益於其放射性配體療法Lutathera的持續臨床應用和市場擴張。

同時，市場正大力研發生長抑制素類似物的緩釋製劑，旨在減輕慢性症狀管理帶來的治療負擔。與標準的每月注射或短效注射劑不同，這些新一代皮下緩釋製劑旨在提供更長時間的穩定藥物釋放，從而提高患者的長期依從性和生活品質。這一發展趨勢得到了專業生物技術公司的大量投資支持。根據Camulus公司於2025年2月發布的“2024年全年報告”，其總收入成長了48%，為推進CAM2029的關鍵性臨床項目提供了必要的資金。 CAM2029是一種正在研發用於治療神經內分泌腫瘤的長效Octreotide製劑。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球類癌症候群腹瀉治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（化療、生長抑制素類似物（SSA）療法、其他）
    • 按最終使用者（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美類癌症候群腹瀉治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲類癌症候群腹瀉治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區類癌症候群腹瀉治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲類癌症候群腹瀉治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美類癌症候群腹瀉治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球類癌症症候群腹瀉治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Lexicon Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • Pfizer Inc.
  • Hutchison China MediTech Limited
  • Progenics Pharmaceuticals
  • Ipsen Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Helsinn Group
  • Omega Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19776

The Global Carcinoid Syndrome Diarrhea Treatment Market is projected to expand from USD 4.21 Billion in 2025 to USD 6.08 Billion by 2031, reflecting a compound annual growth rate of 6.32%. This market encompasses pharmacological interventions, including tryptophan hydroxylase inhibitors and somatostatin analogs, designed to manage the debilitating gastrointestinal symptoms resulting from metastatic neuroendocrine tumors. Growth is largely driven by the increasing prevalence of neuroendocrine neoplasms and improvements in molecular imaging that facilitate earlier and more accurate disease detection before significant progression occurs. For instance, the 'European Neuroendocrine Tumor Society' noted in '2024' that approximately 30% of patients with well-differentiated small intestine neuroendocrine tumors present with carcinoid syndrome symptoms, underscoring the expanding patient pool and the critical need for effective symptomatic therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.21 Billion
Market Size 2031USD 6.08 Billion
CAGR 2026-20316.32%
Fastest Growing SegmentSomatostatin Analog (SSA) Therapy
Largest MarketNorth America

Despite these positive indicators, the market faces substantial hurdles due to the frequent misdiagnosis of the condition. Symptoms often resemble common gastrointestinal issues such as Irritable Bowel Syndrome, leading to considerable delays in accurate identification and subsequent treatment administration. This diagnostic latency impedes patients from accessing effective therapeutic regimens in a timely manner and limits the potential revenue realization for manufacturers operating within this specialized sector.

Market Driver

The growing prevalence of neuroendocrine tumors is significantly increasing the patient population that requires long-term management for carcinoid syndrome diarrhea. As diagnostic tools like molecular imaging become more accessible, clinicians are detecting a larger number of patients with well-differentiated neoplasms before the disease reaches a critical stage, creating a sustained demand for interventions to control refractory gastrointestinal symptoms. According to the NET Research Foundation's September 2025 report, 'Neuroendocrine Cancer on the Rise', the age-adjusted incidence rate of neuroendocrine neoplasms in the United States has risen to 8.52 per 100,000 people. This escalating disease burden has fueled resilient commercial demand for established symptomatic treatments; for example, Ipsen reported in 2025 that sales of the somatostatin analog Somatuline increased by 5.6% throughout 2024, driven by the expanding cohort of patients needing chronic symptom control.

Furthermore, the market is being propelled by rising research and development investments in targeted therapies that offer potent alternatives to conventional injectable regimens. Pharmaceutical developers are aggressively advancing clinical programs for novel oral agents, such as next-generation somatostatin receptor agonists, aimed at improving efficacy and patient compliance where standard therapies are insufficient. A significant milestone occurred in November 2025 when Crinetics Pharmaceuticals announced in its 'Phase 3 CAREFNDR Trial Update' that the first patient had been randomized in a pivotal study for paltusotine, an investigational oral therapy designed to reduce flushing and bowel movement frequency. These initiatives highlight the industry's strategic shift toward delivering more effective and convenient solutions for the substantial number of patients living with uncontrolled carcinoid syndrome.

Market Challenge

The expansion of the Global Carcinoid Syndrome Diarrhea Treatment Market is significantly hindered by diagnostic latency, a challenge stemming from the frequent misidentification of underlying neuroendocrine tumors. Because symptoms like abdominal pain and chronic diarrhea closely mimic prevalent functional disorders such as Irritable Bowel Syndrome (IBS), patients often endure years of ineffective symptom management before the malignancy is correctly identified. This delay restricts market potential by postponing the initiation of necessary pharmacological interventions, effectively shortening the window during which manufacturers can generate revenue from specialized therapies like somatostatin analogs and tryptophan hydroxylase inhibitors.

This difficulty in timely identification is compounded by the relative rarity of these tumors, which results in low clinical suspicion among general practitioners. Data from the 'American Cancer Society' in '2025' indicates that the annual incidence of gastrointestinal neuroendocrine tumors is approximately 1 to 2 cases per 100,000 people. Due to this low occurrence rate, primary care providers rarely encounter the condition, increasing the likelihood that symptoms are attributed to more common ailments. Consequently, a large portion of the addressable patient population remains untreated or undiagnosed for extended periods, artificially suppressing the demand for targeted symptomatic therapies.

Market Trends

The emergence of Peptide Receptor Radionuclide Therapy (PRRT) is significantly transforming the treatment landscape for refractory carcinoid syndrome diarrhea, shifting from a focus solely on tumor reduction to becoming a critical option for symptom control. Clinicians are increasingly adopting targeted radioligand therapies, such as lutetium Lu 177 dotatate, to suppress the hypersecretion of serotonin and bioactive amines in patients who no longer respond to conventional somatostatin analogs. This trend toward using nuclear medicine for symptomatic management is reflected in the strong commercial performance of leading agents; for instance, Novartis reported a 12% increase in net sales in its January 2025 'Annual Report 2024', a growth trajectory largely driven by the continued clinical uptake and market expansion of its radioligand therapy, Lutathera.

Simultaneously, the market is observing a concentrated effort to develop extended-release formulations of somatostatin analogs aimed at reducing the treatment burden associated with chronic symptom management. Unlike standard monthly or short-acting injectables, these next-generation subcutaneous depots are designed to provide consistent drug delivery over extended intervals, thereby improving long-term patient adherence and quality of life. This developmental trend is supported by significant financial investment from specialized biotechnology firms; as reported by Camurus in its February 2025 'Full Year Report 2024', total revenues surged by 48%, providing the capital necessary to advance pivotal clinical programs for their investigational long-acting octreotide depot, CAM2029, for neuroendocrine tumors.

Key Market Players

  • Novartis AG
  • Lexicon Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • Pfizer Inc.
  • Hutchison China MediTech Limited
  • Progenics Pharmaceuticals
  • Ipsen Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Helsinn Group
  • Omega Laboratories Ltd.

Report Scope

In this report, the Global Carcinoid Syndrome Diarrhea Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carcinoid Syndrome Diarrhea Treatment Market, By Therapy Type

  • Chemotherapy
  • Somatostatin Analog (SSA) Therapy
  • Others

Carcinoid Syndrome Diarrhea Treatment Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Carcinoid Syndrome Diarrhea Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carcinoid Syndrome Diarrhea Treatment Market.

Available Customizations:

Global Carcinoid Syndrome Diarrhea Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Chemotherapy, Somatostatin Analog (SSA) Therapy, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. South America Carcinoid Syndrome Diarrhea Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Carcinoid Syndrome Diarrhea Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carcinoid Syndrome Diarrhea Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lexicon Pharmaceuticals
  • 15.3. Ipsen Biopharmaceuticals
  • 15.4. Pfizer Inc.
  • 15.5. Hutchison China MediTech Limited
  • 15.6. Progenics Pharmaceuticals
  • 15.7. Ipsen Pharma
  • 15.8. Teva Pharmaceutical Industries Ltd.
  • 15.9. Helsinn Group
  • 15.10. Omega Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer